The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

PurposeThis multicenter, open-label, phase Ib/II study aimed to assess the efficacy and safety of cadonilimab, a humanized, tetravalent, bispecific antibody plus lenvatinib in first-line treatment of advanced hepatocellular carcinoma (aHCC).MethodsPatients with histologically confirmed aHCC were inc...

Full description

Bibliographic Details
Main Authors: Qian Qiao, Chun Han, Sisi Ye, Juan Li, Guoliang Shao, Yuxian Bai, Aibing Xu, Meili Sun, Wei Wang, Jian Wu, Ming Huang, Lijie Song, Luke Huang, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Bai
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
cadonilimab
lenvatinib
BsA
bi-specific antibody
hepatocellular carcinoma
HCC
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1238667/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1238667/full

Similar Items